<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01318525</url>
  </required_header>
  <id_info>
    <org_study_id>ALF-5755_P2_ALF</org_study_id>
    <nct_id>NCT01318525</nct_id>
  </id_info>
  <brief_title>Efficacy &amp; Safety of ALF-5755 in Patients With Nonacetaminophen Severe Acute Hepatitis &amp; Early Stage Acute Liver Failure</brief_title>
  <official_title>A Multicentre, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy and the Safety of ALF-5755 in Patients With Nonacetaminophen Severe Acute Hepatitis and Early Stage Acute Liver Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alfact Innovation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alfact Innovation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acute liver failure is a rare but dramatic disease, often affecting young people, marked by
      the sudden loss of liver function in a person without preexisting liver disease.

      ALF-5755 has been shown to promote cell survival after apoptotic or oxidative stress, and
      liver cell regeneration in primary cultures and in vivo. ALF-5755 may become, in this
      dramatic disease with high unmet medical need, a future therapy for the treatment of patients
      suffering from severe acute hepatitis (SAH) and acute liver failure (ALF) not due to
      acetaminophen overdose, where liver transplantation is the sole treatment in the absence of
      spontaneous recovery.

      The primary objective of the study is to evaluate the efficacy of ALF-5755 versus placebo.

      A minimum of 60 patients will be recruited into the study in the following two treatment
      groups:

        -  Group A: approximately 30 patients will receive ALF-5755

        -  Group B: approximately 30 patients will receive placebo (physiological saline solution:
           0.9% NaCl)

      Patients will receive 10 mg (25 ml) of ALF5755 or placebo every 12 hours over 3 days in slow
      intravenous infusions over 10 minutes using automatic syringes.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2010</start_date>
  <completion_date type="Anticipated">September 2012</completion_date>
  <primary_completion_date type="Anticipated">May 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of change of Prothrombin Rate initiation</measure>
    <time_frame>Over a period of 72 hours from baseline</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of change of Factor V (FV) plasma level</measure>
    <time_frame>Over a period of 72 hours from baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of change of international normalized ratio (INR)</measure>
    <time_frame>Over a period of 72 hours from baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of change of alanine transaminases (ALT) plasma level</measure>
    <time_frame>Over a period of 72 hours from baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of change of aspartate transaminases (AST) plasma level</measure>
    <time_frame>Over a period of 72 hours from baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Hepatic Encephalopathy Grade (HE grade)</measure>
    <time_frame>Over a period of 72 hours from baseline</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Liver Failure, Acute</condition>
  <arm_group>
    <arm_group_label>ALF-5755</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline solution (0.9% NaCl)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ALF-5755</intervention_name>
    <description>10 mg (25 ml) given in slow intravenous infusion over 10 minutes with an automatic syringe</description>
    <arm_group_label>ALF-5755</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline solution (0.9% NaCl)</intervention_name>
    <description>25 ml given in slow intravenous infusion over 10 minutes with an automatic syringe</description>
    <arm_group_label>Saline solution (0.9% NaCl)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A signed written informed consent from patient or from patient's next of kin or from
             an authorized person according to local procedures

          -  Early stage acute liver failure OR severe acute hepatitis defined as:

          -  15% ≤ PR &lt; 50%

          -  No hepatic encephalopathy, OR grade I or II encephalopathy (Appendix E)

          -  Presumed acute illness onset of less than 26 weeks

          -  No evidence of underlying chronic liver disease

          -  Patient who can receive first treatment dose within the first 48 hours after
             biological baseline assessment

          -  Age ≥ 18 and ≤ 65 years

          -  Contraception (only for females of childbearing potential) to be taken throughout the
             study until D21. Sole mechanic contraceptives, such as condoms, are advised. Note:
             Oral contraceptives may have contraindications in case of severe acute hepatitis and
             acute liver failure

          -  Patient affiliated to social security insurance system.

        Exclusion Criteria:

          -  Acetaminophen-induced hepatitis defined as acetaminophen intake &gt; 4 g/day, at least
             once in the 7 days prior to baseline

          -  Shock liver (ischemic hepatopathy) OR HELLP syndrome OR Budd-Chiari syndrome OR
             intrahepatic malignancy

          -  Serum creatinine ≥ 180 μmol/L

          -  Body Mass Index (BMI) ≥ 35

          -  Septic shock requiring administration of inotropic drugs

          -  Uncontrolled active bleeding

          -  Patients who received fresh frozen plasma, PPSB (Prothrombin-Proconvertin-Stuart-B),
             or vitamin K infusion over the last 48 hours

          -  Patient receiving liver support device treatment, including but not exclusively
             bioartificial liver (BAL), Extracorporeal Liver Assist Device (ELAD), transgenic pig
             perfusion

          -  Patient receiving hemodialysis, hemofiltration or hemodiafiltration treatment

          -  Intractable arterial hypotension (arterial systolic blood pressure equal to or below
             70 mmHg) present or require inotropic drugs at baseline

          -  Human Immunodeficiency Virus (HIV) positive patient

          -  Active cancer

          -  Pregnancy or breast-feeding

          -  Surgery within 4 weeks prior to baseline, or unsolved surgical disease outside liver
             transplantation.

          -  Patient included in another clinical trial within 4 weeks prior to baseline

          -  Patient with organ or bone-marrow allograft

          -  Absolute contra-indication to liver transplantation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Amouyal</last_name>
    <role>Study Director</role>
    <affiliation>Alfact Innovation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Paul Amouyal</last_name>
    <phone>+33 1 45 59 35 66</phone>
    <email>amouyal.paul@wanadoo.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU de Besançon</name>
      <address>
        <city>Besançon Cedex</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Vincent Di Martino</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Clermont-Ferrand</name>
      <address>
        <city>Clermont-Ferrand Cedex 1</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Armand Abergel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Beaujon</name>
      <address>
        <city>Clichy</city>
        <zip>92110</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>François Durand</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Grenoble</name>
      <address>
        <city>Grenoble Cedex 9</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Vincent Leroy</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Claude Huriez</name>
      <address>
        <city>Lille cedex</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Philippe Mathurin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Croix-Rousse</name>
      <address>
        <city>Lyon</city>
        <zip>69004</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Si Nafa Si Ahmed</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Conception</name>
      <address>
        <city>Marseille Cedex 5</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Danielle Botta Fridlund</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint-Eloi</name>
      <address>
        <city>Montpellier Cedex 5</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Dominique Larrey</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital de l'Archet 2</name>
      <address>
        <city>Nice</city>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Jean Gugenheim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Antoine</name>
      <address>
        <city>Paris Cedex 12</city>
        <zip>75571</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Nicolas Carbonell</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital La Pitié Salpétrière</name>
      <address>
        <city>Paris Cedex 13</city>
        <zip>75651</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Marika Rudler</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hépatobiliaire Paul Brousse</name>
      <address>
        <city>Villejuif Cedex</city>
        <zip>94804</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Didier Samuel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Christa L, Felin M, Morali O, Simon MT, Lasserre C, Brechot C, Sève AP. The human HIP gene, overexpressed in primary liver cancer encodes for a C-type carbohydrate binding protein with lactose binding activity. FEBS Lett. 1994 Jan 3;337(1):114-8.</citation>
    <PMID>8276102</PMID>
  </reference>
  <reference>
    <citation>Hoofnagle JH, Carithers RL Jr, Shapiro C, Ascher N. Fulminant hepatic failure: summary of a workshop. Hepatology. 1995 Jan;21(1):240-52. Review.</citation>
    <PMID>7806160</PMID>
  </reference>
  <reference>
    <citation>Iovanna JL, Dagorn JC. The multifunctional family of secreted proteins containing a C-type lectin-like domain linked to a short N-terminal peptide. Biochim Biophys Acta. 2005 May 25;1723(1-3):8-18. Epub 2005 Jan 21. Review.</citation>
    <PMID>15715980</PMID>
  </reference>
  <reference>
    <citation>Kondo T, Suda T, Fukuyama H, Adachi M, Nagata S. Essential roles of the Fas ligand in the development of hepatitis. Nat Med. 1997 Apr;3(4):409-13.</citation>
    <PMID>9095174</PMID>
  </reference>
  <reference>
    <citation>Lasserre C, Christa L, Simon MT, Vernier P, Bréchot C. A novel gene (HIP) activated in human primary liver cancer. Cancer Res. 1992 Sep 15;52(18):5089-95.</citation>
    <PMID>1325291</PMID>
  </reference>
  <reference>
    <citation>Lieu HT, Batteux F, Simon MT, Cortes A, Nicco C, Zavala F, Pauloin A, Tralhao JG, Soubrane O, Weill B, Bréchot C, Christa L. HIP/PAP accelerates liver regeneration and protects against acetaminophen injury in mice. Hepatology. 2005 Sep;42(3):618-26.</citation>
    <PMID>16116631</PMID>
  </reference>
  <reference>
    <citation>Lieu HT, Simon MT, Nguyen-Khoa T, Kebede M, Cortes A, Tebar L, Smith AJ, Bayne R, Hunt SP, Bréchot C, Christa L. Reg2 inactivation increases sensitivity to Fas hepatotoxicity and delays liver regeneration post-hepatectomy in mice. Hepatology. 2006 Dec;44(6):1452-64.</citation>
    <PMID>17133485</PMID>
  </reference>
  <reference>
    <citation>Polson J, Lee WM; American Association for the Study of Liver Disease. AASLD position paper: the management of acute liver failure. Hepatology. 2005 May;41(5):1179-97.</citation>
    <PMID>15841455</PMID>
  </reference>
  <reference>
    <citation>Simon MT, Pauloin A, Normand G, Lieu HT, Mouly H, Pivert G, Carnot F, Tralhao JG, Brechot C, Christa L. HIP/PAP stimulates liver regeneration after partial hepatectomy and combines mitogenic and anti-apoptotic functions through the PKA signaling pathway. FASEB J. 2003 Aug;17(11):1441-50.</citation>
    <PMID>12890698</PMID>
  </reference>
  <verification_date>April 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 17, 2011</study_first_submitted>
  <study_first_submitted_qc>March 17, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2011</study_first_posted>
  <last_update_submitted>April 4, 2011</last_update_submitted>
  <last_update_submitted_qc>April 4, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 5, 2011</last_update_posted>
  <responsible_party>
    <name_title>Paul Amouyal</name_title>
    <organization>Alfact Innovation</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Failure</mesh_term>
    <mesh_term>Liver Failure, Acute</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

